Scientists have completed phenotypic screening of a large collection of potent chemical inhibitors (known as MMV Malaria Box), against pathogenic parasites toxoplasma gondii and plasmodium falciparum, causative agents of human toxoplasmosis and malaria. This knowledge opens up new avenues to study unique stages of infectious cycle that are affected by inhibitor classes towards anti-parasitic drug development.